Cytokinetics, Inc. Stock Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call | |
05-13 | Transcript : Cytokinetics, Incorporated - Special Call |
Sales 2024 * | 9.7M 13.2M | Sales 2025 * | 75.25M 102M | Capitalization | 6.28B 8.55B |
---|---|---|---|---|---|
Net income 2024 * | -490M -667M | Net income 2025 * | -466M -634M | EV / Sales 2024 * | 644 x |
Net cash position 2024 * | 33.92M 46.16M | Net cash position 2025 * | 417M 567M | EV / Sales 2025 * | 78 x |
P/E ratio 2024 * |
-12.6
x | P/E ratio 2025 * |
-14.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.45% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 75 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
1st Jan change | Capi. | |
---|---|---|
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |